Novocure Receives FDA IDE Approval for its PANOVA 3 Phase 3 Pivotal Clinical Trial in Advanced Pancreatic Cancer

PANOVA 3 will determine the efficacy and safety of Tumor Treating Fields in combination with nab-paclitaxel and gemcitabine as a frontline treatment for unresectable locally advanced pancreatic cancer Tumor Treating Fields in combination with nab-paclitaxel and gemcitabine more than doubled progression free survival and the one-year survival rate compared to historical controls in Novocure’s phase …

Novocure Receives Reimbursement Approval for Optune® in Japan for the Treatment of Newly Diagnosed Glioblastoma

Japan represents the largest medical device market in which Novocure has received governmental reimbursement for Optune for the treatment of newly diagnosed glioblastoma ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ:NVCR) announced today that the Japanese Ministry of Health, Labour and Welfare has approved the recommendation by Japan’s Central Social Insurance Medical Council (Chuikyo) to provide reimbursement …

Novocure to Present at Two Upcoming Investor Conferences in December

ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ:NVCR) announced today that it will participate in two upcoming investor conferences in December. Asaf Danziger, Novocure’s Chief Executive Officer, and Wilco Groenhuysen, Novocure’s Chief Financial Officer, will participate in a fireside chat at the Nasdaq 37th International Investor Conference on December 5, 2017, in London. Mr. Danziger and Mr. …

Patients Who Used Optune® More Than 90 Percent of the Time Had the Greatest Chance of Survival in Novocure’s EF-14 Trial: A Median Survival of 24.9 Months from Randomization and a Five-Year Survival of 29.3 Percent

Increased compliance with Optune predicted survival in Novocure’s phase 3 pivotal EF-14 trial in newly diagnosed glioblastoma An Optune compliance threshold as low as 50 percent correlated with significantly improved outcomes in patients treated with Optune together with temozolomide versus patients treated with temozolomide alone ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ:NVCR) announced today results from …

Novocure Announces 28 Presentations on Tumor Treating Fields from Externally Led Clinical Research and Analysis at 22nd Annual Meeting of the Society for Neuro-Oncology

In total, 60 abstracts on Tumor Treating Fields, including two oral presentations, will be presented The volume of Tumor Treating Fields presentations marks a record number of abstracts for Novocure at this conference ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ:NVCR) announced today 28 presentations on Tumor Treating Fields from externally led clinical research and analysis at …

Novocure Announces 10 Presentations on Simulation Studies Aiming to Optimize Treatment Delivery of Tumor Treating Fields at 22nd Annual Meeting of the Society for Neuro-Oncology

Simulation research supports commitment to advance engineering of Tumor Treating Fields delivery systems In total, 60 abstracts on Tumor Treating Fields, including two oral presentations, will be presented The volume of Tumor Treating Fields presentations marks a record number of abstracts for Novocure ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ: NVCR) announced today 10 presentations on …

Novocure Announces 13 Preclinical Presentations Highlighting Data on Tumor Treating Fields’ Mechanism of Action at 22nd Annual Meeting of the Society for Neuro-Oncology

An oral presentation will focus on the induction of autophagy by Tumor Treating Fields In total, 60 abstracts on Tumor Treating Fields, including two oral presentations, will be presented The volume of Tumor Treating Fields presentations marks a record number of abstracts for Novocure at this conference ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ:NVCR) announced today …

Novocure Announces Six Clinical Presentations on Novocure’s Phase 3 Pivotal EF-14 Trial Data in Newly Diagnosed Glioblastoma at 22nd Annual Meeting of the Society for Neuro-Oncology

An oral presentation will focus on how compliance and treatment duration may predict survival in newly diagnosed glioblastoma patients treated with Optune® together with temozolomide In total, 54 abstracts on Tumor Treating Fields, including two oral presentations, will be presented The volume of Tumor Treating Fields presentations marks a record number of abstracts ST. HELIER, …

Novocure Announces Data Presentations at the IASLC 18th World Conference on Lung Cancer

The conference is the world’s largest meeting dedicated to lung cancer and other thoracic malignancies ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ: NVCR) announced today five data presentations at the International Associations for the Study of Lung Cancer (IASLC) 18thWorld Conference on Lung Cancer, October 15 to October 18 in Yokohama, Japan. “We look forward to …